Clinical trial
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
NCT05537025 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 30, 2023
- Completion date
- September 5, 2025
- Enrollment
- 105 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.